Skip to main content
    B

    BioRestorative Therapies Inc (BRTX)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $1.34
    -0.08 (-5.63%)

    Market Cap: $1.96M

    Last updated: Nov 17, 2026 at 4:10 PM ET

    BioRestorative Therapies Inc (BRTX) Statistics

    Updated Nov 17, 2026. Figures from company filings and market prices; estimates from consensus analysts.

    BioRestorative Therapies (BRTX) has a market cap of $1.96M. It kept -3089.55% of revenue as net income over the last 12 months. Its share count is up 112.13% from a year earlier.

    Total Valuation

    Market Cap$1.96M
    Latest price (Nov 17, 2026)$1.34

    Key Dates

    The next earnings report is expected on Mar 24, 2027, covering the quarter ending Dec 31, 2026.

    Next Earnings DateMar 24, 2027 (expected)
    Last Earnings DateNov 11, 2026
    Fiscal Year EndDecember

    Share Statistics

    The share count rose 99.72% in the quarter ended Mar 31, 2026 and grew 63.01% a year over 2 years.

    Shares Outstanding17.73M
    Shares Change (YoY)+112.13%
    Shares Change (QoQ)+99.72%
    Share Count Growth (2Y CAGR)+63.01%

    Valuation Ratios

    Sales and book value multiples are 66.4x and 7.9x. Its year-end P/S ranged from 100.6x to 971.1x from 2020 to 2025.

    P/S Ratio66.4x
    Forward P/S6.3x
    P/B Ratio7.9x
    P/TBV Ratio9.4x

    Valuation history and multiples

    Price Statistics

    The stock is down 94.96% over 52 weeks and trades 30.93% below its 50-day average.

    Beta (1Y)1.58
    52-Week Change-94.96%
    1-Month Change-16.25%
    3-Month Change-68.59%
    6-Month Change-63.51%
    5-Year Change-99.50%
    10-Year Change-100.00%
    Total Return (1Y)-94.96%
    Total Return (3Y CAGR)-66.97%
    Total Return (5Y CAGR)-60.53%
    Return vs SPY (1Y)-106.16%
    Max Drawdown (1Y)-95.31%
    Max Drawdown (3Y)-98.06%
    Sharpe Ratio (1Y)-1.99
    Correlation with SPY (1Y)0.15
    50-Day Average$1.94
    200-Day Average$5.02
    52-Week Range$0.14 to $2.93
    RSI (14 Days)32.8
    Average Volume (20 Days)26.18K

    The 5 and 10 year changes compare month-end closes, adjusted for splits, through Oct 2026.

    Price chart

    Financial Position

    Current assets cover 2.35x current liabilities, and total debt is 0.01x shareholder equity.

    Current Ratio2.35x
    Quick Ratio2.35x
    Debt / Equity0.01x
    Interest Coverage67.54x

    Returns and Efficiency

    Return on invested capital is -289.87% and return on equity is -365.43% over the last 12 months.

    Return on Equity (ROE)-365.43%
    Return on Assets (ROA)-238.27%
    Return on Invested Capital (ROIC)-289.87%
    Asset Turnover0.05x
    Receivables Turnover24.85x

    Scores

    BRTX has an Altman Z-Score of -50.43, in the distress zone below 1.81, and a Piotroski F-Score of 3 of 9, in the average band of 3 to 7.

    Altman Z-Score-50.43
    Altman Z ZoneDistress
    Piotroski F-Score3 of 9
    Piotroski StrengthAverage

    Income Statement

    Revenue of $357.87K over the last 12 months is down 8.47% from the 12 months before.

    Revenue$357.87K
    Revenue Growth (YoY)-8.47%
    Gross Profit$329.55K
    Operating Income-$14.23M
    Pretax Income-$11.06M
    Net Income-$11.06M
    EBITDA-$11.02M
    Reported EPS (TTM)-$2.04

    Trailing 12 months through Mar 31, 2026.

    Full financial statements

    Balance Sheet

    Shareholder equity funds 65.30% of the $4.64M in total assets.

    Cash and Equivalents$3.11M
    Total Debt$34.52K
    Net Cash$3.08M
    Net Cash Per Share$0.17
    Working Capital$2.19M
    Shareholder Equity$3.03M
    Book Value Per Share$0.17
    Tangible Book Value$2.51M
    Tangible Book Per Share$0.14
    Total Assets$4.64M
    Total Liabilities$1.61M

    Balance sheet as of Mar 31, 2026.

    Full balance sheet

    Cash Flow

    After $79.67K of capital spending, operating cash flow left -$11.90M of free cash flow.

    Operating Cash Flow-$11.82M
    Capital Expenditures$79.67K
    Free Cash Flow-$11.90M
    FCF Per Share-$8.61
    Depreciation and Amortization$210.60K

    Trailing 12 months through Mar 31, 2026.

    Full cash flow statement

    Margins

    The operating margin is -3975.00%.

    Gross Margin92.09%
    Operating Margin-3975.00%
    Pretax Margin-3089.55%
    Net Margin-3089.55%
    EBITDA Margin-3078.69%
    FCF Margin-3324.57%
    Gross Margin (5Y Average)97.27%

    Growth

    Revenue grew 44.27% a year over 3 years.

    Revenue Growth (3Y CAGR)+44.27%
    Revenue Growth (5Y CAGR)+36.11%

    Revenue and profit by year

    Dividends and Yields

    BRTX does not pay a dividend.

    Buyback Yield-26.56%
    Shareholder Yield-25.50%

    Stock Splits

    The last split was a 1-for-20 reverse split on Sep 8, 2026.

    Last Split DateSep 8, 2026
    Split TypeReverse split
    Split Ratio1:20

    Peer Position

    Against 3 similar companies, BRTX has the highest P/S.

    P/S Ratio66.4x vs 14.6x median
    Revenue Growth (Trailing 4 Quarters, YoY)-8.47% vs -100.00% median

    Competitors compared

    Analyst Forecast

    Consensus estimates put revenue growth at 104.21% a year over the next 2 fiscal years.

    Revenue Growth Forecast (2Y CAGR)+104.21%

    Analyst estimates by year

    Price Target

    Analyst price targets are part of paid GNG plans. See plans

    Frequently Asked Questions About BRTX

    What is BRTX's market cap?

    BioRestorative Therapies has a market cap of $1.96M.

    How many shares of BRTX are outstanding?

    BioRestorative Therapies has 17.73M shares outstanding. The count is up 112.13% from a year earlier.

    Does BRTX pay a dividend?

    No. BioRestorative Therapies does not pay a dividend.

    How much debt does BRTX have?

    BioRestorative Therapies has $34.52K of total debt and $3.11M of cash and equivalents, a net cash position of $3.08M.